Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 15/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30513985 | 0.86 | CPS1 (0.58) | CPS1HPGDALDH1A1MEN1LMNA | |
| SCHEMBL1051747 | 0.80 | CPS1 (0.63) | CPS1HPGDALDH1A1MEN1LMNA | |
| SCHEMBL531399 | 0.80 | ALDH1A1 (0.65) | CPS1HPGDALDH1A1MEN1LMNA | |
| SCHEMBL29639738 | 0.80 | ALDH1A1 (0.65) | CPS1HPGDALDH1A1MEN1LMNA | |
| SCHEMBL15226106 | 0.79 | CPS1 (0.61) | CPS1HPGDALDH1A1MEN1LMNA | |
| SCHEMBL72082 | 0.79 | CPS1 (0.61) | CPS1HPGDALDH1A1MEN1LMNA | |
| SCHEMBL1555099 | 0.79 | CPS1 (0.61) | CPS1HPGDALDH1A1MEN1LMNA | |
| SCHEMBL1554929 | 0.79 | CPS1 (0.61) | CPS1HPGDALDH1A1MEN1LMNA | |
| SCHEMBL11246241 | 0.79 | CPS1 (0.50) | CPS1HPGDALDH1A1LMNAMAPK1 | |
| SCHEMBL28053004 | 0.77 | CPS1 (0.59) | CPS1HPGDALDH1A1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193228-B2 | Substituted imidazole as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100022598-A1 | Substituted inmidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME LLC | 2010-01-28 | — | — | US | disclosed |
| EP-2091937-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008051406-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022598-A1 | Substituted inmidazoles as bombesin receptor subtype-3 modulators | BRS3, INSR, INSRR | CPS1 3266/4885HPGD 4197/4885ALDH1A1 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.